Advertisement
Kyntra Bio, Inc.

Kyntra Bio, Inc. (KYNB) Stock Competitors & Peer Comparison

See (KYNB) competitors and their performances in Stock Market.

KYNBNASDAQ
HealthcareMedical - Pharmaceuticals
$7.24
$0.30(4.32%)
U.S. Market opens in 0h 20m
Advertisement

Peer Comparison Table: Medical - Pharmaceuticals Industry

Detailed financial metrics including price, market cap, P/E ratio, and more.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
KYNB$7.24+4.32%29.3M-0.59-$12.34N/A
RPRX$56.23+2.82%24.2B11.09$5.07+1.64%
WBA$11.98+0.50%10.4B-1.64-$7.29+4.17%
KNSA$59.20+4.06%4.5B65.78$0.90N/A
TRLV$8.99+5.52%1.5B893.00$0.01N/A
HROWL$25.61+0.19%1.4BN/AN/AN/A
AVLN$30.71+5.97%1.4B-1.41-$21.83N/A
HROWM$26.03-0.08%1.3BN/AN/AN/A
CGEM$18.40-0.43%1.1B-5.48-$3.36N/A
XOMAP$25.49+0.12%307.5M14.00$1.82+8.46%
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

KYNB vs RPRX Comparison June 2026

KYNB plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, KYNB stands at 29.3M. In comparison, RPRX has a market cap of 24.2B. Regarding current trading prices, KYNB is priced at $7.24, while RPRX trades at $56.23.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

KYNB currently has a P/E ratio of -0.59, whereas RPRX's P/E ratio is 11.09. In terms of profitability, KYNB's ROE is -2.34%, compared to RPRX's ROE of +0.13%. Regarding short-term risk, KYNB is more volatile compared to RPRX. This indicates potentially higher risk in terms of short-term price fluctuations for KYNB.Check RPRX's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions